Botox denials in California external review
In the California DMHC record, independent physician reviewers decided 174 published external-review cases involving Botoxand overturned the plan’s denial in 66.1%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Chronic Migraine | 51 | 80.4% |
| Migraine | 49 | 59.2% |
| Cervical Dystonia | 12 | 75% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 115 | 61.7% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 59 | 74.6% |
What the reviewers wrote
Where the denial was overturned
Physician 1This case concerns a 34-year-old male who has a long-standing history of migraine headaches. In addition, he experiences chronic pain related to carpel tunnel location of median nerve injury. His physician has indicated the patient has attempted multiple medications for pain management including Neurontin, Topamax, tricyclic antidepressants, beta-blockers, Maxalt and calcium channel blockers without relief. The patient reports he has received Botox injections in the past with some degree of headache relief. Therefore, he has requested authorization and coverage for Botox injections. The Health Plan has denied this request indicating the requested therapy is considered investigational for treatment of the patient’s migraine headaches.I would recommend the denial be overturned.
Physicain 1The patient is a 17-year-old female who has had daily headaches since May 2004 that have seriously impacted her quality of life. She has undergone extensive diagnostic imaging. The patient has tried a variety of medications without relief. Her neurologist has diagnosed her with classic migraine. A request has been made for authorization and coverage for Botox injections for treatment of the patient’s headaches. The Health Plan has denied the request on the basis that Botox is considered experimental for treatment of the patient’s medical condition.This young female appears to have status migrainosis or transformed migraine. To date, the efficacy of Botox for treatment of migraines has not been established in the medical literature. Though there is great interest in Botox and studies are in progress, there are no randomized, controlled trials.
Where the denial was upheld
Physician 1: The patient is a 63-year-old female who experiences headaches and possibly has comorbid depression. The patient’s provider indicates the patient has failed treatment with Pamelor, Midrin, Paxil, Effexor, Tylenol and ibuprofen. The patient wishes to pursue treatment with Botox. The Health Plan has denied coverage for the requested therapy on the basis it is considered investigational.The documentation provided suggests the patient has muscle tension type headaches rather than migraine headaches. In addition, it appears the patient has comorbid depression. In cases such at this, patients receive the most benefit from prophylactic headache medications such as Depakote, calcium channel blockers or Topamax combined with Paxil for depression. There are a number of effective and well tolerated medications for the treatment of muscle tension headaches.
Physician 1: The patient is a 54-year-old female with a 15-year history of episodic migraines occurring three to four times per month. Her migraines have been poorly responsive to triptans. The patient received two courses of Botox injections for which she has requested reimbursement. In addition, the patient has requested authorization for future Botox injections.The patient reports she had virtually complete resolution of migraines for six months following Botox therapy. The submitted clinical records do not document a trial of preventive therapy other than Botox.The Health Plan has denied coverage for Botox therapy on the basis it is considered investigational for the treatment of migraine headaches.The submitted records provide no objective evidence the patient has been tried on usual preventive therapy such has beta-blockers, tricyclic anti-depressants, Topamax or Depakote.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Put this treatment in the complete diagnosis-and-drug graph, with the migraine-only denominator disclosed separately: migraine, CGRP drug and Botox denial evidence guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Botox, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY